ערך בספרים למניה: Portage Biotech Inc. (PRTG)

Extended patent protection of intellectual property ensures Portage Biotech Inc. (PRTG) sustainable long-term margins. The trend in book value per share confirms this thesis, with the indicator recorded at 1.26. The company develops high-precision cancer treatment methods via immune cell activation, reducing therapy toxicity. Within professional circles, the brand is valued as a reliable developer with a pragmatic investment profile.

Book value per share determines the portion of net assets attributable to a single security by dividing equity by the number of shares, establishing a fundamental floor for the business value. By analyzing the trend of the book value per share, an investor can see how the capitalization of Portage Biotech Inc. (PRTG) developments in precision cancer immunotherapy transforms into a tangible material support for the stock price.